Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS
In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS).
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Acute Coronary Syndromes, Arrhythmias and Clinical EP, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Interventions and ACS
Keywords: EaglesEyeView, Blood Pressure, Glucagon-Like Peptide-1 Receptor, Atrial Fibrillation, Biomarkers, Heart Failure, Acute Coronary Syndrome, Drug-Eluting Stents, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
